Revista Espanola de Cardiologia Suplementos最新文献_第5页

Sistema renina-angiotensina-aldosterona y COVID19. Implicaciones clínicas 肾素-血管紧张素-醛固酮系统与covid - 19。临床意义

Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30032-7

Pedro Caravaca Pérez , Laura Morán Fernández , María Dolores García-Cosio , Juan F. Delgado

引用次数: 4

Papel de los lípidos en la ateroesclerosis 脂质在动脉粥样硬化中的作用

Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30023-6

Fernando Civeira , Victoria Marco-Benedí , Ana Cenarro

引用次数: 0

Hitos históricos en el tratamiento hipolipemiante antes de la era de los inhibidores de la proproteina convertasa subtilisina/kexina tipo 9 枯草赖氨酸/克辛9型原蛋白转换酶抑制剂时代之前降脂治疗的历史里程碑

Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30024-8

Pedro-Botet Juan, Elisenda Climent, David Benaiges

引用次数: 1

Coordinación de unidades de rehabilitación cardiaca y de insuficiencia cardiaca. Continuidad asistencial en la insuficiencia cardiaca 协调心脏康复和心力衰竭单位。心力衰竭的持续护理

Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30017-0

José Manuel García Pinilla , Vicente Arrarte

引用次数: 1

Fisiopatología de la enfermedad cardiovascular en pacientes con COVID-19. Isquemia, trombosis y disfunción cardiaca COVID-19患者心血管疾病的病理生理学。缺血、血栓形成和心脏功能障碍

Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30028-5

José Rozado , Ana Ayesta , César Morís , Pablo Avanzas

{"title":"Fisiopatología de la enfermedad cardiovascular en pacientes con COVID-19. Isquemia, trombosis y disfunción cardiaca","authors":"José Rozado , Ana Ayesta , César Morís , Pablo Avanzas","doi":"10.1016/S1131-3587(20)30028-5","DOIUrl":"10.1016/S1131-3587(20)30028-5","url":null,"abstract":"<div><p>Cardiovascular complications are highly prevalent in patients with COVID-19 and frequently lead to hospitalization, death and long-term morbidity. This article describes the principle pathophysiological mechanisms involved in the development of these complications. After the initial viremia, viralinvasión and replication occurs in the lungs, accompanied by immune system activation, cytokine release and the induction of a proinflammatory state, with sepsis and multiorgan failure. Myocardial injury could be due to the direct effect of viralinvasión and a local inflammatory response or to the indirect effect of inappropriate systemic inflammation involving a cytokine storm. Furthermore, the development of a prothrombotic state, together with vascular disease due to the virus, could trigger ischemic and thrombotic events secondary to microvascular damage or to the destabilization of pre-existing atheromatous plaque. New research is needed to reveal the pathophysiological mechanisms underlying these cardiovascular events and to support the development of effective new treatments.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30028-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56636360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Aplicabilidad de los consensos de expertos de unidades de insuficiencia cardiaca/rehabilitación cardiaca y RehaCtivAP con respecto a la COVID-19 心力衰竭/心脏康复和康复部门专家共识对新冠肺炎的适用性

Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30021-2

Vicente Arrarte , Raquel Campuzano

引用次数: 2

Anticoagulación del paciente anciano pluripatológico con fibrilación auricular no valvular: papel del rivaroxabán 老年多病理性非瓣膜房颤患者的抗凝作用:利伐沙班的作用

Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30011-X

Antoni Riera-Mestre , Miguel Camafort , Jose María Suriñach , Francisco José Muñoz Rodríguez , Ferran Padilla , Jaume Francisco-Pascual , José Mateo Arranz , Antonio Martínez Rubio , Roger Villuendas Sabaté , Román Freixa-Pamias , Carmen Suárez Fernández , Amparo Santamaría

{"title":"Anticoagulación del paciente anciano pluripatológico con fibrilación auricular no valvular: papel del rivaroxabán","authors":"Antoni Riera-Mestre , Miguel Camafort , Jose María Suriñach , Francisco José Muñoz Rodríguez , Ferran Padilla , Jaume Francisco-Pascual , José Mateo Arranz , Antonio Martínez Rubio , Roger Villuendas Sabaté , Román Freixa-Pamias , Carmen Suárez Fernández , Amparo Santamaría","doi":"10.1016/S1131-3587(20)30011-X","DOIUrl":"10.1016/S1131-3587(20)30011-X","url":null,"abstract":"<div><p>Atrial fibrillation is common in elderly patients. Although vitamin K antagonists have been widely used for many years, they have a number of limitations in elderly patients, who are particularly susceptible to bleeding and in whom anticoagulation control is poorer than in the general population. Direct oral anticoagulants have been shown to be a better therapeutic option for these patients, not only because they are simpler to use, but also because they are more effective and safer than vitamin K antagonists. Moreover, their performance in practice is generally consistent with that in pivotal clinical trials. Nevertheless, there is a tendency to administer inappropriate doses to elderly patients, generally underdosing, particularly in certain subgroups. This can result in less protection against stroke without any clear reduction in bleeding risk. Rivaroxaban has been widely studied in the elderly population, not only in clinical trials, but also in a range of studies in routine clinical practice – findings have been highly consistent. According to these studies, and compared to vitamin K antagonists, rivaroxaban reduces the risk of stroke without increasing the rate of fatal bleeding, with a net clinical benefit in patients with nonvalvular atrial fibrillation and a high thromboembolic risk.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30011-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56636090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Paciente con alto riesgo cardiovascular y fibrilación auricular: papel del rivaroxabán 高危心血管和心房颤动患者:利伐沙班的作用

Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30014-5

Vivencio Barrios , David Vivas , Felipe Atienza Fernández , Miguel Ángel Arias , Raquel Diaz Simón , Aquilino Sánchez Purificación , Gonzalo Barón-Esquivias

{"title":"Paciente con alto riesgo cardiovascular y fibrilación auricular: papel del rivaroxabán","authors":"Vivencio Barrios , David Vivas , Felipe Atienza Fernández , Miguel Ángel Arias , Raquel Diaz Simón , Aquilino Sánchez Purificación , Gonzalo Barón-Esquivias","doi":"10.1016/S1131-3587(20)30014-5","DOIUrl":"10.1016/S1131-3587(20)30014-5","url":null,"abstract":"<div><p>Traditionally the primary aim of anticoagulation in patients with atrial fibrillation was the prevention of stroke. However, these patients actually have numerous comorbidities that also have a substantial impact on prognosis and that must be treated. These considerations should also play a role in selecting the best anticoagulant treatment for patients with a high cardiovascular risk. In general, direct oral anticoagulants have consistently been shown to have superior efficacy and safety to warfarin, irrespective of whether patients have a history of stroke, transient ischemic attack, diabetes, renal insufficiency or myocardial infarction. In particular, studies have shown that rivaroxaban is associated with a lower risk of myocardial infarction and fewer renal complications than warfarin. In a subgroup study of the ROCKET-AF trial, it was found that rivaroxaban significantly reduced cardiovascular mortality in patients with diabetes mellitus (by 20%). Moreover, studies carried out in routine clinical practice showed that the drug significantly reduces the risk of both major cardiovascular events and peripheral artery disease. As a result, rivaroxaban could be considered the preferred option for anticoagulation in patients with nonvalvular atrial fibrillation and a high cardiovascular risk, given the additional benefits it provides in this population.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30014-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56635767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novedades en la guía de práctica clínica de la Sociedad Europea de Cardiología en dislipemias: el peso de la evidencia 欧洲心脏病学会血脂异常临床实践指南的更新:证据的权重

Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30026-1

Carlos Escobar , Vivencio Barrios

引用次数: 0

COVID-19. Las consecuencias sociales, sanitarias y cardiovasculares 新型冠状病毒肺炎社会、健康和心血管后果

Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30027-3

Ángel Cequier Fillat , José Ramón González-Juanatey

引用次数: 5